Somewhere in a lab right now, scientists are reading the mutations inside a single patient’s tumour and turning them into medicine built for that person alone. That is not a hypothetical any more. It is the basis of a treatment that just cleared Phase 3 trials, the final and toughest stage of human testing a drug goes through before it can be considered for approval.
WHAT MERCK AND MODERNA ANNOUNCED
On August 19, Merck and Moderna announced that their personalised mRNA cancer vaccine, called intismeran autogene, succeeded in a Phase 3 trial for melanoma when combined with Keytruda, Merck’s immunotherapy drug. This is the first time any individualised cancer vaccine has succeeded at this stage of testing, and the first mRNA-based cancer therapy to do so.
HOW THE VACCINE ACTUALLY WORKS
This is where the word personalised earns its meaning. After a patient’s tumour is surgically removed, doctors take a sample of it and sequence its DNA, looking for the specific mutations unique to that person’s cancer. No two patients’ tumours carry the same set. Scientists then code up to 34 of these mutations into a single mRNA shot built only for that patient. Once injected, the vaccine trains the immune system to recognise and destroy any remaining cancer cell carrying that exact mutation signature. It is precision medicine taken to its furthest point, a treatment with only one patient’s biology in mind.
WHY KEYTRUDA ALONE WAS NOT ENOUGH
For years, the standard of care for high risk melanoma after surgery has been Keytruda by itself. It works by helping the immune system spot and attack cancer cells it might otherwise miss, and it has been the backbone of post-surgery melanoma treatment. But even with Keytruda, a meaningful number of patients relapse, most often within the first two years, and most often with the cancer spreading to distant parts of the body rather than staying local. That has remained a persistent gap in melanoma care.
INSIDE THE TRIAL
The trial, called INTerpath-001, enrolled 1,137 patients with high-risk, completely resected melanoma, stages IIB through IV. Patients were randomised to receive either the personalised vaccine alongside Keytruda, or Keytruda alone, for roughly a year of treatment. The trial tracked two outcomes: how long before the cancer returned, known as recurrence-free survival, and how long before it spread to distant parts of the body, known as distant metastasis-free survival. The vaccine and Keytruda combination outperformed Keytruda alone on both.
The companies have not yet released the exact percentages. Those numbers are being reserved for presentation at an international medical meeting and for submission to regulators. The safety profile, according to the companies, showed no new concerns, consistent with earlier studies of the same combination, where the most common side effects were fatigue, injection site pain, and chills.
WHY THIS REACHES BEYOND MELANOMA
Globally, more than 330,000 new melanoma cases were diagnosed in 2022. In the US alone, over 112,000 new cases and more than 8,500 deaths are projected this year. But the bigger significance of this trial has little to do with melanoma specifically. Melanoma was simply the fastest cancer to prove the underlying technology works. Merck and Moderna are already running versions of the same personalised vaccine platform in trials for lung cancer, bladder cancer, and kidney cancer.
That is likely why Moderna CEO Stphane Bancel did not compare this to another cancer drug launch. He compared it to November 16, 2020, the day Moderna’s Covid vaccine trial results were announced, and called this a new chapter in cancer care.
THE CAVEAT WORTH KEEPING IN MIND
This is topline data from a company announcement. It has not yet been peer reviewed or published in a medical journal. The specific efficacy numbers are still to come, and the trial continues to track overall survival, widely considered the most meaningful endpoint in oncology. If the fuller data holds up, this could mark one of the first real proofs that cancer treatment can be built one tumour, one mutation, one patient at a time.
– Ends
Source link
[ad_3]
